vs
Side-by-side financial comparison of Amphastar Pharmaceuticals, Inc. (AMPH) and Life360, Inc. (LIF). Click either name above to swap in a different company.
Amphastar Pharmaceuticals, Inc. is the larger business by last-quarter revenue ($183.1M vs $146.0M, roughly 1.3× Life360, Inc.). Life360, Inc. runs the higher net margin — 88.8% vs 13.3%, a 75.5% gap on every dollar of revenue. On growth, Life360, Inc. posted the faster year-over-year revenue change (26.4% vs -1.8%). Life360, Inc. produced more free cash flow last quarter ($36.6M vs $24.6M). Over the past eight quarters, Life360, Inc.'s revenue compounded faster (36.6% CAGR vs 3.2%).
Amphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company. It was incorporated in May 2004 and primarily develops, manufactures, and sells inhalation and intranasal products.
Life360, Inc. develops family-focused safety and connectivity platforms. Core offerings include real-time location sharing, emergency alerts, driving behavior analysis tools and identity theft protection. It serves consumer markets across North America, Europe and Asia-Pacific, with most revenue from tiered premium subscription plans.
AMPH vs LIF — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $183.1M | $146.0M |
| Net Profit | $24.4M | $129.7M |
| Gross Margin | 46.8% | 75.1% |
| Operating Margin | 19.4% | 6.1% |
| Net Margin | 13.3% | 88.8% |
| Revenue YoY | -1.8% | 26.4% |
| Net Profit YoY | -35.7% | 1425.9% |
| EPS (diluted) | $0.51 | $1.53 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $183.1M | $146.0M | ||
| Q3 25 | $191.8M | $124.5M | ||
| Q2 25 | $174.4M | $115.4M | ||
| Q1 25 | $170.5M | $103.6M | ||
| Q4 24 | $186.5M | $115.5M | ||
| Q3 24 | $191.2M | $92.9M | ||
| Q2 24 | $182.4M | $84.9M | ||
| Q1 24 | $171.8M | $78.2M |
| Q4 25 | $24.4M | $129.7M | ||
| Q3 25 | $17.4M | $9.8M | ||
| Q2 25 | $31.0M | $7.0M | ||
| Q1 25 | $25.3M | $4.4M | ||
| Q4 24 | $38.0M | $8.5M | ||
| Q3 24 | $40.4M | $7.7M | ||
| Q2 24 | $37.9M | $-11.0M | ||
| Q1 24 | $43.2M | $-9.8M |
| Q4 25 | 46.8% | 75.1% | ||
| Q3 25 | 51.4% | 78.0% | ||
| Q2 25 | 49.6% | 78.4% | ||
| Q1 25 | 50.0% | 80.6% | ||
| Q4 24 | 46.5% | 74.0% | ||
| Q3 24 | 53.3% | 75.4% | ||
| Q2 24 | 52.2% | 75.0% | ||
| Q1 24 | 52.4% | 76.7% |
| Q4 25 | 19.4% | 6.1% | ||
| Q3 25 | 13.2% | 4.6% | ||
| Q2 25 | 24.2% | 1.7% | ||
| Q1 25 | 21.9% | 2.1% | ||
| Q4 24 | 24.2% | 4.9% | ||
| Q3 24 | 29.8% | -5.3% | ||
| Q2 24 | 30.3% | -2.8% | ||
| Q1 24 | 27.9% | -8.2% |
| Q4 25 | 13.3% | 88.8% | ||
| Q3 25 | 9.0% | 7.9% | ||
| Q2 25 | 17.8% | 6.1% | ||
| Q1 25 | 14.8% | 4.2% | ||
| Q4 24 | 20.4% | 7.4% | ||
| Q3 24 | 21.1% | 8.3% | ||
| Q2 24 | 20.8% | -12.9% | ||
| Q1 24 | 25.1% | -12.5% |
| Q4 25 | $0.51 | $1.53 | ||
| Q3 25 | $0.37 | $0.11 | ||
| Q2 25 | $0.64 | $0.08 | ||
| Q1 25 | $0.51 | $0.05 | ||
| Q4 24 | $0.74 | $0.14 | ||
| Q3 24 | $0.78 | $0.09 | ||
| Q2 24 | $0.73 | $-0.15 | ||
| Q1 24 | $0.81 | $-0.14 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $282.8M | $494.3M |
| Total DebtLower is stronger | $608.7M | — |
| Stockholders' EquityBook value | $788.8M | $548.2M |
| Total Assets | $1.6B | $959.7M |
| Debt / EquityLower = less leverage | 0.77× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $282.8M | $494.3M | ||
| Q3 25 | $276.2M | $455.7M | ||
| Q2 25 | $231.8M | $432.7M | ||
| Q1 25 | $236.9M | $168.9M | ||
| Q4 24 | $221.6M | $159.2M | ||
| Q3 24 | $250.5M | $159.0M | ||
| Q2 24 | $217.8M | $160.8M | ||
| Q1 24 | $289.6M | $73.4M |
| Q4 25 | $608.7M | — | ||
| Q3 25 | $608.6M | — | ||
| Q2 25 | $607.7M | — | ||
| Q1 25 | $603.9M | — | ||
| Q4 24 | $601.6M | — | ||
| Q3 24 | $596.4M | — | ||
| Q2 24 | $586.9M | — | ||
| Q1 24 | $594.0M | $5.2M |
| Q4 25 | $788.8M | $548.2M | ||
| Q3 25 | $776.7M | $391.4M | ||
| Q2 25 | $757.5M | $366.7M | ||
| Q1 25 | $751.3M | $376.3M | ||
| Q4 24 | $732.3M | $358.5M | ||
| Q3 24 | $727.7M | $339.7M | ||
| Q2 24 | $713.3M | $326.7M | ||
| Q1 24 | $672.4M | $239.8M |
| Q4 25 | $1.6B | $959.7M | ||
| Q3 25 | $1.7B | $787.5M | ||
| Q2 25 | $1.6B | $753.6M | ||
| Q1 25 | $1.6B | $455.4M | ||
| Q4 24 | $1.6B | $441.6M | ||
| Q3 24 | $1.5B | $427.4M | ||
| Q2 24 | $1.5B | $405.9M | ||
| Q1 24 | $1.6B | $318.8M |
| Q4 25 | 0.77× | — | ||
| Q3 25 | 0.78× | — | ||
| Q2 25 | 0.80× | — | ||
| Q1 25 | 0.80× | — | ||
| Q4 24 | 0.82× | — | ||
| Q3 24 | 0.82× | — | ||
| Q2 24 | 0.82× | — | ||
| Q1 24 | 0.88× | 0.02× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $32.9M | $36.8M |
| Free Cash FlowOCF − Capex | $24.6M | $36.6M |
| FCF MarginFCF / Revenue | 13.4% | 25.1% |
| Capex IntensityCapex / Revenue | 4.5% | 0.2% |
| Cash ConversionOCF / Net Profit | 1.35× | 0.28× |
| TTM Free Cash FlowTrailing 4 quarters | $121.2M | $86.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $32.9M | $36.8M | ||
| Q3 25 | $52.6M | $26.4M | ||
| Q2 25 | $35.6M | $13.3M | ||
| Q1 25 | $35.1M | $12.1M | ||
| Q4 24 | $29.0M | $12.3M | ||
| Q3 24 | $60.0M | $6.3M | ||
| Q2 24 | $69.1M | $3.3M | ||
| Q1 24 | $55.3M | $10.7M |
| Q4 25 | $24.6M | $36.6M | ||
| Q3 25 | $47.2M | $25.6M | ||
| Q2 25 | $25.0M | $12.7M | ||
| Q1 25 | $24.4M | $11.9M | ||
| Q4 24 | $16.6M | $11.2M | ||
| Q3 24 | $46.2M | $6.3M | ||
| Q2 24 | $63.1M | $3.2M | ||
| Q1 24 | $46.5M | — |
| Q4 25 | 13.4% | 25.1% | ||
| Q3 25 | 24.6% | 20.6% | ||
| Q2 25 | 14.3% | 11.0% | ||
| Q1 25 | 14.3% | 11.5% | ||
| Q4 24 | 8.9% | 9.7% | ||
| Q3 24 | 24.1% | 6.8% | ||
| Q2 24 | 34.6% | 3.8% | ||
| Q1 24 | 27.1% | — |
| Q4 25 | 4.5% | 0.2% | ||
| Q3 25 | 2.8% | 0.6% | ||
| Q2 25 | 6.1% | 0.6% | ||
| Q1 25 | 6.3% | 0.1% | ||
| Q4 24 | 6.7% | 1.0% | ||
| Q3 24 | 7.2% | 0.0% | ||
| Q2 24 | 3.3% | 0.1% | ||
| Q1 24 | 5.1% | 0.0% |
| Q4 25 | 1.35× | 0.28× | ||
| Q3 25 | 3.03× | 2.70× | ||
| Q2 25 | 1.15× | 1.90× | ||
| Q1 25 | 1.39× | 2.75× | ||
| Q4 24 | 0.76× | 1.45× | ||
| Q3 24 | 1.48× | 0.83× | ||
| Q2 24 | 1.82× | — | ||
| Q1 24 | 1.28× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
LIF
Segment breakdown not available.
